ATS Medical Announces Australian Regulatory Approval for ATS 3f Aortic Bioprosthesis
MINNEAPOLIS, Feb. 5 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI ), manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced today that the Australian Therapeutic Goods Administration (TGA) has granted approval for commercialization of the A...ATS Medical Announces FDA Approval of the ATS 3f Aortic Bioprosthesis
MINNEAPOLIS, Oct. 30 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI ), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced it has received U.S. Food and Drug Administration (FDA) approval for the ATS 3f(R) Aortic Bioprosthesis. (Lo...ATS Medical Provides Update on Clinical Progress of ATS 3f Enable Aortic Bioprosthesis
MINNEAPOLIS, Nov. 28 /PRNewswire-FirstCall/ -- ATS Medical Inc. (Nasdaq: ATSI ), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced that a total of 47 patients have now undergone aortic valve replacement with its sutureless ATS 3f Enable(TM) A...ATS Medical Announces Second Quarter 2009 Results
...erlin presented five-year single center follow-up data on the ATS 3F Aortic bioprosthesis highlighting the valve's excellent safety and performance profile. Dr... U.K. presented five-year hemodynamic performance data on the ATS 3F Aortic bioprosthesis as assessed by valve energy loss and pressure gradient. Dr. Jin's findings...ATS Medical Announces Participation in 45th Annual Society of Thoracic Surgeons Meeting
...volutionary next generation stentless pericardical aortic tissue valve that is unlike any other. Post-approval commercialization of the ATS 3f Aortic bioprosthesis continues with the valve's unique design and compelling clinical benefits generating enthusiasm and product demand among U.S. surgeons. The ATS...Mosaic Aortic Bioprosthesis with CINCH Advanced Implant System
Description: Mosaic, the third generation tissue valve from Medtronic, is the only third generation stented tissue valve available. The Mosaic valve builds upon three decades of tissue valve experience and is an excellent choice for patients who require aortic or mitral valve replacement with a tissue valve. Fo...Hancock® Standard Mitral Bioprosthesis
Description: The Hancock Standard Mitral bioprosthesis is a portrait of dependability, with predictable results based on 25 years of clinical use. Documented long-term performance makes it an excellent choice for patients requiring mitral valve replacement--particularly elderly patients and those with coronary ...Hancock II Aortic Bioprostheses with CINCH Advanced Implant System
Description:... The Hancock II bioprosthesis from Medtronic has more than 15 years of proven clinical experience. Worldwide clinical studies demonstrate that the freedom from structural valve det...Hancock® II Aortic Bioprostheses
Description:... The Hancock® II bioprosthesis from Medtronic has more than 15 years of proven clinical experience. Worldwide clinical studies demonstrate that the freedom from structural valve det...Hancock® II Mitral Bioprostheses
Description:... The Hancock® II bioprosthesis from Medtronic has more than 15 years of proven clinical experience. Worldwide clinical studies demonstrate that the freedom from structural valve det...ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis
MINNEAPOLIS, Dec. 8 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI ), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced it has received FDA clearance for the marketing of the ATS 3f(R) Aortic Bioprosthesis that includes a new sewing t...ATS Medical Announces First North American Commercial Implant of the ATS 3f Aortic Bioprosthesis
Follows Canadian regulatory approval of the ATS 3f Valve MINNEAPOLIS, April 10 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI ), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced the first North American commercial implant ...ATS Medical Announces Record Quarterly Revenue and Gross Profit
...he ATS 3f Aortic Bioprosthesis. The Company submitted answers to the FDA in March 2008. Management continues to expect that the ATS 3f Aortic bioprosthesis will be approved in the second half of 2008. -- ATS 3f Enable(TM) Aortic Bioprosthesis: Enrollment continues to progress with excellent cli...